Innate Pharma Partners with Sobi to Advance Lacutamab for T-cell Lymphoma

Innate Pharma and Swedish Orphan Biovitrum (Sobi) have established a strategic partnership for lacutamab, a treatment for T-cell lymphoma. Innate Pharma will lead the confirmatory Phase 3 TELLOMAK-3 study, aiming for accelerated approval in Sézary syndrome. Sobi will gain exclusive global commercialization rights upon potential accelerated approval, which could bring a new therapeutic option to patients.